We're continuing to
see inventory growth, but we're not seeing enough new projects to replace what was in the pipeline,» said Hargrave.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain
growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of
inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not
see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
«Although we've now
seen two consecutive quarters of strong market
growth, we believe the strong market performance has less to do with strengthening demand and more to do with increased appetite from the channel for
inventory,» added Linn Huang, research director, Devices & Displays.
Natural Gas Natural gas futures were among the quarter's key decliners -LRB--7.5 %, to US$ 2.73 per million British thermal units) as production
growth outweighed seasonal consumption and higher exports of the fuel.1 Spot prices
saw an even larger drop of 20.6 % (to US$ 2.81) as the support of December's weather - related demand spikes faded and a more normal winter pattern developed.1 Natural gas generally took its downward price cues from elevated US production and
growth in the natural gas - focused rig count, which increased from 179 to 194 in March alone.2 Despite the price drop, traders remained optimistic given surging US shale - gas exports and a supply deficit that was 20 % larger than the five - year average at March - end, the biggest in four years.3 Moreover, total natural gas
inventories of 1.38 trillion cubic feet were nearly 33 % below their year - ago level.3 Meanwhile, the market appeared focused on an anticipated production surge (2018 is projected to be a record
growth year for gas supplies) and may have overlooked intensifying demand as US exports increasingly helped drain supplies.
When you look over the whole recovery / expansion period, the swings in
inventories more or less cancel out, and you can
see from the second chart that up until recently, investment
growth has played a larger - than - usual role in driving GDP
growth.
«The IEA
sees strong demand
growth and declining OECD
inventories at the moment.
Breaking the GDP report down, we
see that in addition to overall modest strength in the economy (
growth was still off from the fourth quarter's 2.9 %), the upturn was helped individually by positive contributions from nonresidential fixed investment, exports, private
inventory investment, federal government spending, and state and local government spending.
I've inverted the
inventory curve to highlight the close relationship between the two metrics, so what you're
seeing is an inverse relationship between
growth in the
inventories - to - shipments ratio (blue) and economic output (red), as defined by non-defense durable good shipments, excluding aircraft.
Historically, a declining
growth rate in the
inventories - to - sales ratio has coincided with increased economic output, as we
see in the chart below.
One market segment that's expected to
see continued strong price
growth is entry - level housing, which is struggling with a shortage of
inventory.
The housing demand and lack of
inventory is so great, that if supply does not increase, we could
see a upwards of 5 percent
growth in median home prices within the Austin - Round Rock MSA.
In contrast, the underperformers
saw inventory grow of just 0.4 percent in 2014 and will only
see growth of 1.2 percent over the next couple of years.
Redevelopment and rental professionals like the Chicago - based Mack Companies, which turns foreclosed homes into quality single - family rentals, are
seeing significant
growth — so much so that the federal government is looking at this sector of the housing industry for answers as to how to address the continuing high
inventory of distressed properties.
«As we head into 2019 and beyond, we expect to
see these
inventory increases take hold and provide relief for first - time homebuyers and drive sales
growth,» Vivas says.
«Home buyers are benefiting from slower price
growth due to the much - needed, rising
inventory levels
seen since the beginning of the year,» he said.
The additional
inventory could lead to more balanced prices, moving away from the spike in annual
growth we have
seen lately.»
«Strong demand generated by several years of economic
growth continues to drive prices higher, and if
inventory remains sluggish to come onto the market, we could
see price
growth accelerate.»
The rate of
inventory growth isn't really surprising, however, because it reflects the jump in starts that we
saw 18 to 24 months ago.
That's one of the most aggressive
inventory growth rates
seen anywhere across the country.
Going forward, we may begin to
see a divergence, as
inventory growth headwinds have been developing for assisted living, while construction in independent living remains comparatively tempered,» says Mike Hargrave, NIC's chief market & data strategist.
Based on a comparison of Monthly Supply of Houses and New One - Family Houses Sold, one can easily
see that demand for houses is rising but
inventories are decreasing that is causing price
growth.
In terms of household
growth, apartment
inventory growth and job creation, this region of the U.S.
saw the largest
growth rates in the five years following the recession.
Like the South, the West region generally
saw solid
growth in households, employment and apartment
inventory since the recovery.
«Those neighborhoods where we
saw incredible
inventory growth from last year also
saw some of the most teardowns according to permits submitted to the city of Chicago.
During those same four quarters, 5 other metropolitan markets
saw annual
inventory growth of less than 0.25 %,» added Harry.
The biggest competition for Canadians, Tuccillo says, are investor groups that are now making unprecedented «bulk investments» — buying dozens of condos or houses at a time in markets, like Florida, which has
seen steady price
growth and the
inventory of homes for sale sink to five months» worth from the glut of 20 months back in 2008.